This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Brolucizumab for visual impairment due to diabetic macular oedema

< Back

Brolucizumab for visual impairment due to diabetic macular oedema


Eye Disease

November 2020

Brolucizumab is in clinical development for the treatment of visual impairment due to diabetic macular oedema (DMO). DMO is a condition affecting the retina, the nerve layer at the back of the eye. The central part of the retina known as the macula, is responsible for fine detail vision, both for near (reading) and for distance. In patients with DMO, the fine meshwork of blood vessels supplying nutrients and oxygen to the macula become damaged and leaky due to the high levels of glucose in the bloodstream in some patients with diabetes. If left untreated, the leakage will potentially permanently damage the retinal nerve cells and eventually produce scarring, which can be irreversible.
Brolucizumab is administered by intravitreal injection. It works by binding with high affinity and blocking multiple isoforms of a substance called vascular endothelial growth factor A (VEGF-A). By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling. Brolucizumab may confer advantages over currently available therapies, potentially allowing for less frequent dosing resulting in a reduced treatment burden. If licensed, will provide a treatment option for patients with visual impairment due to DMO.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts